Selected research
Market Structure
Global Hospital Acquired Pneumonia Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Hospital Acquired Pneumonia Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Hospital Acquired Pneumonia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Hospital Acquired Pneumonia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Hospital Acquired Pneumonia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Hospital Acquired Pneumonia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Hospital Acquired Pneumonia Drugs include Merck, GlaxoSmithKline, Bayer, AstraZeneca, Valneva, Meiji Holdings, Cubist Pharmaceutical, Basilea Pharmaceutica and Aridis Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Hospital Acquired Pneumonia Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Hospital Acquired Pneumonia Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Hospital Acquired Pneumonia Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hospital Acquired Pneumonia Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Hospital Acquired Pneumonia Drugs Segment by Company
Merck
GlaxoSmithKline
Bayer
AstraZeneca
Valneva
Meiji Holdings
Cubist Pharmaceutical
Basilea Pharmaceutica
Aridis Pharmaceutical
Achaogen
Hospital Acquired Pneumonia Drugs Segment by Type
Phase II
Early Phase (Phase I & II)
Hospital Acquired Pneumonia Drugs Segment by Application
Hospital Pharmacies
Drug Store
Retail Pharmacies
E-Commerce
Hospital Acquired Pneumonia Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hospital Acquired Pneumonia Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hospital Acquired Pneumonia Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hospital Acquired Pneumonia Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Hospital Acquired Pneumonia Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hospital Acquired Pneumonia Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hospital Acquired Pneumonia Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Hospital Acquired Pneumonia Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Phase II
- Early Phase (Phase I & II)
Applications
- Hospital Pharmacies
- Drug Store
- Retail Pharmacies
- E-Commerce
Companies covered
- Merck
- GlaxoSmithKline
- Bayer
- AstraZeneca
- Valneva
- Meiji Holdings
- Cubist Pharmaceutical
- Basilea Pharmaceutica
- Aridis Pharmaceutical
- Achaogen
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Hospital Acquired Pneumonia Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Hospital Acquired Pneumonia Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Hospital Acquired Pneumonia Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Hospital Acquired Pneumonia Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Hospital Acquired Pneumonia Drugs Market Dynamics
- 2.1 Hospital Acquired Pneumonia Drugs Industry Trends
- 2.2 Hospital Acquired Pneumonia Drugs Industry Drivers
- 2.3 Hospital Acquired Pneumonia Drugs Industry Opportunities and Challenges
- 2.4 Hospital Acquired Pneumonia Drugs Industry Restraints
3 Hospital Acquired Pneumonia Drugs Market by Manufacturers
- 3.1 Global Hospital Acquired Pneumonia Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Hospital Acquired Pneumonia Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Hospital Acquired Pneumonia Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Hospital Acquired Pneumonia Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Hospital Acquired Pneumonia Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Hospital Acquired Pneumonia Drugs Manufacturers, Product Type & Application
- 3.7 Global Hospital Acquired Pneumonia Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Hospital Acquired Pneumonia Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Hospital Acquired Pneumonia Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Hospital Acquired Pneumonia Drugs Tier 1, Tier 2, and Tier 3
4 Hospital Acquired Pneumonia Drugs Market by Type
- 4.1 Hospital Acquired Pneumonia Drugs Type Introduction
- 4.1.1 Phase II
- 4.1.2 Early Phase (Phase I & II)
- 4.2 Global Hospital Acquired Pneumonia Drugs Sales by Type
- 4.2.1 Global Hospital Acquired Pneumonia Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Hospital Acquired Pneumonia Drugs Sales by Type (2021-2032)
- 4.2.3 Global Hospital Acquired Pneumonia Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Hospital Acquired Pneumonia Drugs Revenue by Type
- 4.3.1 Global Hospital Acquired Pneumonia Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Hospital Acquired Pneumonia Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Hospital Acquired Pneumonia Drugs Revenue Market Share by Type (2021-2032)
5 Hospital Acquired Pneumonia Drugs Market by Application
- 5.1 Hospital Acquired Pneumonia Drugs Application Introduction
- 5.1.1 Hospital Pharmacies
- 5.1.2 Drug Store
- 5.1.3 Retail Pharmacies
- 5.1.4 E-Commerce
- 5.2 Global Hospital Acquired Pneumonia Drugs Sales by Application
- 5.2.1 Global Hospital Acquired Pneumonia Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Hospital Acquired Pneumonia Drugs Sales by Application (2021-2032)
- 5.2.3 Global Hospital Acquired Pneumonia Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Hospital Acquired Pneumonia Drugs Revenue by Application
- 5.3.1 Global Hospital Acquired Pneumonia Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Hospital Acquired Pneumonia Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Hospital Acquired Pneumonia Drugs Revenue Market Share by Application (2021-2032)
6 Global Hospital Acquired Pneumonia Drugs Sales by Region
- 6.1 Global Hospital Acquired Pneumonia Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Hospital Acquired Pneumonia Drugs Sales by Region (2021-2032)
- 6.2.1 Global Hospital Acquired Pneumonia Drugs Sales by Region (2021-2026)
- 6.2.2 Global Hospital Acquired Pneumonia Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Hospital Acquired Pneumonia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Hospital Acquired Pneumonia Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Hospital Acquired Pneumonia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Hospital Acquired Pneumonia Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Hospital Acquired Pneumonia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Hospital Acquired Pneumonia Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Hospital Acquired Pneumonia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Hospital Acquired Pneumonia Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Hospital Acquired Pneumonia Drugs Revenue by Region
- 7.1 Global Hospital Acquired Pneumonia Drugs Revenue by Region
- 7.1.1 Global Hospital Acquired Pneumonia Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Hospital Acquired Pneumonia Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Hospital Acquired Pneumonia Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Hospital Acquired Pneumonia Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Hospital Acquired Pneumonia Drugs Revenue (2021-2032)
- 7.2.2 North America Hospital Acquired Pneumonia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Hospital Acquired Pneumonia Drugs Revenue (2021-2032)
- 7.3.2 Europe Hospital Acquired Pneumonia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Hospital Acquired Pneumonia Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Hospital Acquired Pneumonia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Hospital Acquired Pneumonia Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Hospital Acquired Pneumonia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Merck
- 8.1.1 Merck Company Information
- 8.1.2 Merck Business Overview
- 8.1.3 Merck Hospital Acquired Pneumonia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Merck Hospital Acquired Pneumonia Drugs Product Portfolio
- 8.1.5 Merck Recent Developments
- 8.2 GlaxoSmithKline
- 8.2.1 GlaxoSmithKline Company Information
- 8.2.2 GlaxoSmithKline Business Overview
- 8.2.3 GlaxoSmithKline Hospital Acquired Pneumonia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 GlaxoSmithKline Hospital Acquired Pneumonia Drugs Product Portfolio
- 8.2.5 GlaxoSmithKline Recent Developments
- 8.3 Bayer
- 8.3.1 Bayer Company Information
- 8.3.2 Bayer Business Overview
- 8.3.3 Bayer Hospital Acquired Pneumonia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Bayer Hospital Acquired Pneumonia Drugs Product Portfolio
- 8.3.5 Bayer Recent Developments
- 8.4 AstraZeneca
- 8.4.1 AstraZeneca Company Information
- 8.4.2 AstraZeneca Business Overview
- 8.4.3 AstraZeneca Hospital Acquired Pneumonia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 AstraZeneca Hospital Acquired Pneumonia Drugs Product Portfolio
- 8.4.5 AstraZeneca Recent Developments
- 8.5 Valneva
- 8.5.1 Valneva Company Information
- 8.5.2 Valneva Business Overview
- 8.5.3 Valneva Hospital Acquired Pneumonia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Valneva Hospital Acquired Pneumonia Drugs Product Portfolio
- 8.5.5 Valneva Recent Developments
- 8.6 Meiji Holdings
- 8.6.1 Meiji Holdings Company Information
- 8.6.2 Meiji Holdings Business Overview
- 8.6.3 Meiji Holdings Hospital Acquired Pneumonia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Meiji Holdings Hospital Acquired Pneumonia Drugs Product Portfolio
- 8.6.5 Meiji Holdings Recent Developments
- 8.7 Cubist Pharmaceutical
- 8.7.1 Cubist Pharmaceutical Company Information
- 8.7.2 Cubist Pharmaceutical Business Overview
- 8.7.3 Cubist Pharmaceutical Hospital Acquired Pneumonia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Cubist Pharmaceutical Hospital Acquired Pneumonia Drugs Product Portfolio
- 8.7.5 Cubist Pharmaceutical Recent Developments
- 8.8 Basilea Pharmaceutica
- 8.8.1 Basilea Pharmaceutica Company Information
- 8.8.2 Basilea Pharmaceutica Business Overview
- 8.8.3 Basilea Pharmaceutica Hospital Acquired Pneumonia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Basilea Pharmaceutica Hospital Acquired Pneumonia Drugs Product Portfolio
- 8.8.5 Basilea Pharmaceutica Recent Developments
- 8.9 Aridis Pharmaceutical
- 8.9.1 Aridis Pharmaceutical Company Information
- 8.9.2 Aridis Pharmaceutical Business Overview
- 8.9.3 Aridis Pharmaceutical Hospital Acquired Pneumonia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Aridis Pharmaceutical Hospital Acquired Pneumonia Drugs Product Portfolio
- 8.9.5 Aridis Pharmaceutical Recent Developments
- 8.10 Achaogen
- 8.10.1 Achaogen Company Information
- 8.10.2 Achaogen Business Overview
- 8.10.3 Achaogen Hospital Acquired Pneumonia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Achaogen Hospital Acquired Pneumonia Drugs Product Portfolio
- 8.10.5 Achaogen Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Hospital Acquired Pneumonia Drugs Value Chain Analysis
- 9.1.1 Hospital Acquired Pneumonia Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Hospital Acquired Pneumonia Drugs Production Mode & Process
- 9.2 Hospital Acquired Pneumonia Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Hospital Acquired Pneumonia Drugs Distributors
- 9.2.3 Hospital Acquired Pneumonia Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst